文献速递白血病造血干细胞移植与细胞治疗

IL15激活的CIK细胞异基因造血干细胞移植后首次人体研究:白血病持续缓解与血清治疗相关免疫重建

First-in-Human Study of IL15-Activated Cytokine-Induced Killer Cells After Allogeneic HCT Shows Durable Remission and Serotherapy-Associated Immune Reconstitution in Leukemia.
PubMed 文献 · J Clin Oncol · 2026-04-06

该首次人体、疾病负荷导向的多中心I/II期试验评估供者来源IL15-CIK细胞在53例高危白血病患者异基因移植后的可行性、安全性和疗效。结果显示IL15-CIK单药治疗安全可行,无治疗相关死亡,抢先治疗时完全分子学缓解累积发生率第700天达74%,5年总生存根据治疗意图为20%-71%。

要点

  • IL15-CIK单药移植后输注安全,无广泛慢性GVHD或治疗相关死亡。
  • 抢先治疗时完全分子学缓解累积发生率第700天达74%, salvage仅13%。
  • 5年无进展生存整体50%,儿童AML最高69%;总生存依治疗意图20%-71%。

核心结论

  • IL15-CIK单药治疗高危白血病异基因移植后可行、安全,并显示有前景的复发预防活性。
  • 临床结局强烈受治疗开始时疾病负荷和既往血清治疗影响,支持未来优化患者选择和时机。

研究设计与样本

  • 前瞻性、多中心I/II期试验(EudraCT 2013-005446-11)及相同设计的预试验。
  • 纳入53例成人和儿童高危白血病患者,接受56疗程IL15-CIK单药治疗,移植类型为HLA相合或不合。
  • 治疗意图分为巩固(13%)、抢先(61%)或挽救(27%),共169次输注,单次剂量占29%, adaptable剂量递增方案占71%。
  • 中位随访7.3年。

主要发现

  • 急性GVHD 1-2级和3级分别发生于27%和4%的病例,未观察到广泛慢性GVHD或治疗相关死亡。
  • IL15-CIK相关不良事件主要为轻度。
  • 完全分子学缓解累积发生率在第700天达峰值,抢先治疗为74%,挽救治疗为13%。
  • 5年无进展生存整体为50%,儿童急性髓系白血病最高为69%。
  • 5年总生存巩固治疗为71%,抢先治疗为61%,挽救治疗为20%。

临床怎么用

  • 对于高危白血病异基因移植后患者,可考虑IL15-CIK作为复发预防策略,尤其在抢先治疗时机。
  • 治疗前疾病负荷较低和既往血清治疗类型可能影响IL15-CIK疗效,需个体化选择患者和时机。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Patients with high-risk (HR) leukemia remain at substantial risk of early relapse, treatment-related toxicity, and poor survival, underscoring the need for effective relapse prevention therapies. To our knowledge, this first-in-human, disease burden-guided study evaluated the feasibility, safety, and efficacy of donor-derived allogeneic interleukin-15-activated cytokine-induced killer cells (IL15-CIK) combining T-cell and natural killer cell properties for post-transplant disease control. METHODS: In a prospective, multicenter phase I/II trial (EudraCT 2013-005446-11) and an identically designed pilot study, 53 adult and pediatric patients with HR leukemia received 56 courses of IL15-CIK monotherapy after human leukocyte antigen (HLA)-matched or HLA-mismatched transplantation. Treatment intent was categorized as consolidation (13%), preemptive (61%), or salvage (27%) with 169 infusions administered as a single dose (29%) or according to adaptable dose-escalation regimens (71%). RESULTS: Acute graft-versus-host disease (GVHD) grades 1-2 and grade 3 occurred in 27% and 4% of cases, respectively; no extensive chronic GVHD or treatment-related mortality was observed. IL15-CIK-associated adverse events were predominantly mild. Disease clearance, assessed by the cumulative incidence of complete molecular remission, peaked at day 700, reaching 74% in the preemptive and 13% in the salvage setting. The five-year progression-free survival was 50% overall and highest (69%) in pediatric acute myeloid leukemia. The five-year overall survival (OS) was 71% in the consolidation, 61% in the preemptive, and 20% in the salvage setting. Multivariable analysis demonstrated significantly lower relapse rates with Campath compared with ATG, superior OS in myeloid malignancies, and reduced IL15-CIK efficacy in advanced disease. The median follow-up was 7.3 years. CONCLUSION: IL15-CIK monotherapy is feasible and safe and demonstrates promising relapse-preventive activity after hematopoietic stem-cell transplantation. Clinical outcomes are strongly influenced by disease burden at treatment initiation and previous serotherapy, supporting optimized patient selection and timing in future post-transplant immunotherapeutic strategies.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Rettinger E, Heckl D, Hutter M, et al. First-in-Human Study of IL15-Activated Cytokine-Induced Killer Cells After Allogeneic HCT Shows Durable Remission and Serotherapy-Associated Immune Reconstitution in Leukemia. J Clin Oncol. 2026. PMID: 41941697. doi:10.1200/JCO-25-01966

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。